Sparta Biomedical Discovered First-of-its-kind Ormi Device for Knee Osteoarthritis
Sparta Biomedical has discovered first-of-its-kind Ormi device in patients with focal knee lesions as part of its first-in-human clinical trial.
This innovative device allows surgeons to address cartilage damage, whether or not the underlying bone is involved. After implantation, patients will be closely monitored by study investigators through imaging, physical exams, and self-reported outcomes.
The Ormi device utilises Galene platform, a cutting-edge synthetic cartilage that mimics the properties of natural hyaline cartilage. By integrating Galene with a specially designed titanium stemmed base, the device ensures stable fixation during the repair of cartilage lesions.
Ormi aims to overcome the limitations of current treatments for knee osteoarthritis, offering a potential solution that allows for weight-bearing, full range of motion, and rapid pain relief. Ormi replicates the strength and function of healthy cartilage from day one. This makes it a revolutionary approach to treating this widespread condition.
Ormi stands out as the only device of its kind, addressing the long-standing challenge of helping patients with knee focal lesions regain mobility and alleviate pain swiftly. With limited options available to surgeons worldwide, Ormi offers a unique and much-needed solution.
Knee osteoarthritis affects approximately 651 million people globally, posing significant challenges in terms of patient suffering and healthcare costs. Unlike traditional cartilage regeneration techniques, which take time to grow and are often weaker than natural cartilage,
The US FDA has recognised the device's potential, granting it breakthrough device designation for the treatment of knee osteoarthritis.